Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment

Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment

<b>Objective: </b> Anlotinib hydrochloride is a multitarget tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor, c-Kit, and c-MET; therefore, it exhibits both antitumor and anti-ang...

Full description

Bibliographic Details
Main Authors: Jing Wang, Yizhuo Zhao, Qiming Wang, Li Zhang, Jianhua Shi, Zhehai Wang, Ying Cheng, Jianxing He, Yuankai Shi, Hao Yu, Yang Zhao, Weiqiang Chen, Yi Luo, Xiuwen Wang, Kejun Nan, Faguang Jin, Jian Dong, Baolan Li, Zhujun Liu, Baohui Han, Kai Li
Format: Article
Language:English
Published: China Anti-Cancer Association 2018-12-01
Series:Cancer Biology & Medicine
Subjects:
Non-small cell lung cancer
anlotinib
third- or further-line therapy
prognostic factor analysis
Online Access:http://www.cancerbiomed.org/index.php/cocr/article/view/1305

Internet

http://www.cancerbiomed.org/index.php/cocr/article/view/1305

Similar Items